Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

SC1-PM-10-2017: Búsqueda de empresas e investigadores en el campo de tratamiento antibiótico de la artritis reumatoide

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDDE20160503001
Publicado:
19/07/2016
Caducidad:
12/05/2017
Resumen:
Una pequeña empresa alemana especializada en inmunoquímica busca socios con el fin de preparar una propuesta para el programa Horizonte 2020 (SC1-PM-10-2017). El objetivo del proyecto denominado "Efectividad de las intervenciones sanitarias actuales en el tratamiento de la artritis reumatoide con anticuerpos terapéuticos" es el análisis sistemático del tratamiento de la artritis reumatoide con anticuerpos terapéuticos. Se buscan empresas e institutos de investigación especializados en diagnóstico y tratamiento de la artritis reumatoide.

Details

Tittle:
SC1-PM-10-2017: Looking for business and research partners in rheumatic arthritis therapy with antibodies
Summary:
A German small business active in immunochemistry is looking for partners for a Horizon 2020 (SC1-PM-10-2017) project. The project will be called "Effectiveness of existing healthcare interventions in rheumatic arthritis therapy with therapeutic antibodies". The aim of the project is the systematic analysis of the therapeutic antibodies-based rheumatic arthritis therapy. They look for businesses and research institutes active in diagnostics and rheumatic arthritis treatment.
Description:
A small business from Germany active in the field of biotechnology is looking for partners for the Call "Comparing the effectiveness of existing healthcare interventions in the adult population", SC1-PM-10-2017 in Horizon 2020. The company would like to head the consortium.

The project will be called "Effectiveness of existing healthcare interventions in rheumatic arthritis therapy with therapeutic antibodies". The aim of the project is the systematic analysis of rheumatic arthritis therapy based on therapeutic antibodies. Therefore, the project will address three dimensions of improving the therapy of rheumatic arthitis.
First, the project will analyse comprehensive diagnostic data to elucidate the drug/target interaction.
Second, the project should develop patients-centered therapeutic drug monitoring (TDM) for a personalised drug dose.
And third, the project will analyse the cost effectiveness of the "anti TNF alpha" therapy in rheumatic arthritis patients. This novel therapy coming from cancer treatment aims at curing rhematic arthritis by modifying the inflammatory disease process in the bone affected.

The company has expertise in immunochemistry and will contribute a technology to monitor a free drug, a free antigen and a drug/antigen complex in rheumatic arthritis patient´s sera during therapy.

The company is looking for project partners from Horizon 2020 partner countries with expertise in rheumatic arthitis research and product innovation.
More specifically they look for:
- a small-or-medium-sized business active in rheumatic arthritis diagnostics, biomarker evaluation, proteomics, metabolomics and genetics,
- clinics, universities and research institutes involved in rheumatic arthritis treatment, research and e-health projects,
- medical study design experts and large scale data analyst,
- health economics and public health experts.

The framework conditions of the call are those of a Research -Y- Innovation Action. The direct costs a reimbursed 100%, whereas 20% of the indirect costs are reimbrused. The partners of the project need to be a legal entity established in one of the participating countries of the EU. The budget of the application will be between 4 and 5 Mio EUR.

The deadline for EOIs is 30 June 2016. The deadline for the first stage of applications is 4 October 2016. The deadline for the second stage is 11 April 2017. The project duration will be maximum 48 months.

Partner sought

Partner Sought:
The company is looking for project partners from Horizon 2020 partner countries with expertise in rheumatic arthritis research and product innovation. At the moment, the consortium is still open for different partners, such as other small-or-medium-sized businesses active in rheumatic arthritis diagnostics (such as biomarker evaluation, proteomics, metabolomics and genetics). The consortium is also looking for clinics, universities and research institutes involved in rheumatic arthritis treatment, research and e-health projects. Another partner is needed (research or business) to design the medical study and work with large scale data analysis. The consortium is also looking for health economics and public health experts.
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Dissemination

Programme-call

Evaluation Scheme:
two-stage submission
Anticipated Project Budget:
6 Mio EUR
Coordinator Required:
No
Deadline for Call:
04/10/2016
Project Duration:
208
Project title and Acronym:
Effectiveness of existing healthcare interventions in Rheumatic Arthritis therapy with therapeutic antibodies